Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: IMM
Market: AIM
52-week High/Low: 70.32p / 30.79p
Sector: Pharma & Biotech
Market Cap: 69.24M
Phone: +44 (0)20 7152 4080
Address: 50 Broadway, Westminster, London SW1H 0RG.
Website: www.immupharma.com
ImmuPharma PLC

ImmuPharma PLC

ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

 

***IMMUPHARMA INVESTOR PRESENTATION - FRIDAY 30TH JUNE***

ImmuPharma will be hosting an Investor Presentation and luncheon immediately following the Company’s Annual General Meeting, currently scheduled for Friday 30 June, in the City of London.  Further details will be disclosed when ImmuPharma’s Report and Accounts are posted to shareholders in the next week.  Please contact Lisa Baderoon at [email protected] if you would like to attend this event.

ImmuPharma PLC

www.immupharma.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in ImmuPharma PLC


ImmuPharma PLC Snapshot


ImmuPharma’s strategy and business model is different from many of its peers. We are a risk-adverse company and our management team has extensive experience in senior positions in some of the world’s leading pharmaceutical companies.  

ImmuPharma focuses in developing pioneering and novel drugs in specialist therapeutic areas where there is a distinct lack of existing treatments, avoiding primary care (diseases treated by GPs) where many treatments exist. This is consistent with the trends in the pharmaceutical industry.

Since our foundation, our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value at a relatively low cost, and to work with many leading scientists and doctors. ImmuPharma has exclusive rights to all its intellectual property assets.

Our market strategy is to license our assets to leading international corporations that are well-placed to further develop and/or commercialise our drugs. Our corporate deal with Cephalon Inc. in 2008, for the worldwide rights of our lead drug candidate for the treatment of Lupus, Lupuzor™ is one example of this strategy in action.

ImmuPharma’s drug development and research

ImmuPharma’s low risk-strategy is to capitalize on pioneering research taking place primarily at Europe’s largest fundamental research institution, the Centre National de la Recherche Scientifique (National Center for Scientific Research) or CNRS. The CNRS was founded in 1939 and is a government-funded research organization, under the administrative authority of France's Ministry of Research and has over 30,000 employees and an annual budget of over €3 billion. The CNRS has received many prestigious awards and has produced 17 Nobel laureates and 11 Fields Medal award winners.

We have a significant collaborative research and development agreement with the CNRS, which grants ImmuPharma worldwide exclusive rights to exploit commercially certain discoveries.

Our link with the CNRS allows ImmuPharma access to many scientists and doctors, keeping our costs low by avoiding the constant funding necessary for early stage research.

Alongside our collaborations, we are using innovative technologies to develop a strong proprietary discovery pipeline and patented portfolio of potential new lead compounds.

Business development and corporate deals

ImmuPharma entered into a corporate deal with Cephalon Inc. in 2008, for the worldwide rights of our lead drug candidate for the treatment of Lupus, Lupuzor™ in a $500m plus royalties deal. In late 2011, ImmuPharma regained the rights due to the acquisition of Cephalon by Teva Pharmaceutical Industries. We are now pursuing discussions with other companies for the licensing of Lupuzor™ while also exploring the option of retaining the rights until commercialisation.

ImmuPharma is interested in corporate partnerships for its development assets. Collaborations are core to our strategy and we welcome contacts from other companies interested in partnering with us. Please feel free to contact us at [email protected]

 

Operations

Our operations are focused on pharmaceutical R&D and Business Development. We work closely with our research partner, the Centre National de la Recherche Scientifique in France and we pursue product development both directly ourselves as well as by subcontracting activities to Contract Research Organizations. We have a large network of scientific advisors that provide us with the necessary expertise and input in our activities.

We operate out of three locations in Europe:

  • In the UK, we have our holding company focused on administration, business development/licensing, investor relations and management activities
  • In France, we have part of our R&D activities, including working with the Centre National de la Recherche Scientifique, primarily in Strasbourg, Paris and Bordeaux
  • In Switzerland, we have part of our R&D, business development / licensing and also commercial activities and investor relations

Tim McCarthy - Non-executive Chairman

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing. A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

Dimitri F Dimitriou, MSc - Senior Non-Executive Director & Co-founder

Dimitri F. Dimitriou has 25 years’ experience in the pharmaceutical and biotech industry. Prior to co-founding ImmuPharma, he was Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career in marketing at Novartis (Sandoz) in 1987. He has a degree in biochemistry from Kings College, University of London and an MSc in pathology and toxicology from the Imperial College Medical School.

Dr Franco Di Muzio - Senior Non-Executive Director

Dr. Di Muzio has 40 years experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000. On 6 May 2015 it was announced Dr Di Muzio had been appointed Interim Chairman due to Richard Warr’s ill health.

Dr Stéphane Méry - Non-Executive Director

Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he was Partner at Beringea LLP, a $400m US/UK venture capital fund, where he was responsible for healthcare investments in Europe. Previously, he was the Fund Manager/CEO of the Bloomsbury Bioseed Fund, a Biotech and Medtech investment fund, which was behind the birth of successful companies such as Spirogen (sold to MedImmune), Abzema (listed on AIM), and Canbex, (recently sold to Ipsen). Prior to this, Stéphane was Associate Director, Worldwide Business Development, for SmithKline Beecham (GSK) where he was responsible for the negotiation of several major in-license deals and acquisitions. Before GSK, he was involved in the start-up of Double Helix Development, a successful strategic consultancy company specialising in R&D for the biotech and healthcare industry and recently sold to McCann. Just before, he worked as a management consultant at the American consultancy firm, ZS Associates, specialising on sales and marketing within the pharmaceutical industry. Stéphane is a Doctor in Veterinary Medicine, a trained Veterinary Pathologist, specialising in Nasal Toxicology at the Chemical Industry Institute of Toxicology (CIIT) in North Carolina, and holds an MBA from INSEAD (Fontainebleau).

Dr Robert Zimmer, MD, PhD - President & Chief Science Officer & Co-founder

Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche’s headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO.

Tracy Weimar - Vice President, Operations & Finance

Ms Weimar has spent over 8 years at GlaxoSmithKline and her most recent position there was Director, Worldwide Business Development where she was involved in a number of corporate licensing deals. She has also held a number of positions in health economics, strategy development, sales and marketing. Ms Weimar was a non-executive director for the Avon and Wiltshire Mental Health Partnership NHS Trust responsible for ensuring the Trust was accountable to the public for the services it provided and for the public funds it used. She was a member of both the Audit and Remuneration Committees of the Trust.

Lisa Baderoon - Head of Investor Relations

Lisa Baderoon has spent over 20 years working within the City of London and has been involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their media and investor relations strategies. During this time she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPO’s) and mergers and acquisitions both in the UK and internationally.

U.K.

ImmuPharma plc

50 Broadway

Westminster

London SW1H 0RG

U.K.

Tel: +44 20 7152 4080

Fax: +44 20 7152 4001

 

France

ImmuPharma France S.A.

5, rue du Rhône

F-68100 Mulhouse

France

 

Switzerland

ImmuPharma A.G.

Poststrasse 10

6060 Sarnen OW

Switzerland

Nominated Advisor & Broker
Panmure Gordon, London, U.K.

Public Relations & Investor Relations
[email protected]
Broker Profile, London, U.K.
Dr. Reuter Investor Relations, Germany

Auditors
Nexia Smith & Williamson Audit Limited, London, U.K.

Legal Advisors
Bircham Dyson Bell LLP, London, U.K.
Badertscher Rechtsanwälte AG, Zurich, Switzerland

Patent Agents
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France

Manufacturers
PolyPeptide Group, Strasbourg, France

ImmuPharma PLC Timeline

Columns Including IMM

VIEW ALL

Market Reports Including IMM

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use